p53 Mutation as Plausible Predictor for Endocrine Resistance Therapy in Luminal Breast Cancer

Endocrine therapy resistance in Luminal Breast Cancer is a significant issue to be tackled, but currently, no specific biomarker could be used to anticipate this event. p53 mutation is widely known as one of Breast Cancer’s most prominent genetic alterations. Its mutation could generate various effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Halim, Freda, Azhar, Yohana, Suwarman, Suwarman, Hernowo, Bethy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718986/
https://www.ncbi.nlm.nih.gov/pubmed/36519010
http://dx.doi.org/10.12688/f1000research.108628.2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718986/
https://www.ncbi.nlm.nih.gov/pubmed/36519010
http://dx.doi.org/10.12688/f1000research.108628.2

Ejemplares similares